23andMe has filed for Chapter 11 bankruptcy protection and its co-founder and CEO has resigned as the struggling genetic testing company continues its push to cut costs.

The company said Sunday that it will look to sell “substantially all of its assets” through a court-approved reorganization plan.

The San Francisco-based company also said Anne Wojcicki had resigned as CEO effective immediately but would remain on the company’s board. Her resignation comes about two weeks after a board committee had rejected a nonbinding acquisition proposal from Wojcicki.

Shares of 23andMe Holding Co., which have shed nearly all their value since last spring, plunged below $1 in premarket trading Monday.

The voluntary bankruptcy filing caps months of turmoil for the company, which has struggled to find a profitable business model since going public in 2021.

In September, all of its independent directors resigned in a rare move following negotiations with Wojcicki, who had been trying to take the company private.

The company then announced in November it would lay off 40% of its workforce, or more than 200 employees, and discontinue its therapeutics division.

In January, the board’s special committee said it was exploring strategic alternatives, including a possible sale.

Board Chair Mark Jensen said in a statement the company has determined that a court-supervised sale was “the best path forward to maximize the value of the business.” 23andMe plans to continue operating its business and has $35 million in debtor- in-possession financing from JMB Capital Partners.